Prognostic role of slow vital capacity in amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis
Cohort studies
Epidemiology
Slow vital capacity
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
17
11
2019
accepted:
05
02
2020
revised:
03
02
2020
pubmed:
14
2
2020
medline:
18
3
2021
entrez:
14
2
2020
Statut:
ppublish
Résumé
To compare the prognostic role of FVC and SVC at diagnosis in amyotrophic lateral sclerosis (ALS) patients. We included all patients from the Piemonte and Valle D'Aosta ALS register (PARALS) who had been diagnosed with ALS between 1995 and 2015 and underwent spirometry at diagnosis. Survival was considered as time to death/tracheostomy; to assess the prognostic value in typical trial timeframes, survival at 12 and 18 months was calculated too. Cox proportional hazard regression models adjusted by sex, age at diagnosis, diagnostic delay, onset site, and ALSFRS-R total score at the moment of diagnosis were used to assess the prognostic role of FVC and SVC. A total of 795 ALS patients underwent spirometry at diagnosis during the study period. Four hundred and sixteen (52.3%) performed both FVC and SVC, whereas the others performed FVC only. FVC and SVC values were highly correlated (r = 0.92, p < 0.001) in the overall population and slightly less correlated in patients with bulbar onset (r = 0.86, p < 0.001). Both FVC and SVC proved to have a prognostic role with comparable hazard ratios (HRs) (HR 1.83, 95% CI 1.48-2.27 and 1.88, 95% CI 1.51-2.33, respectively). When considering typical trial timeframes, HRs remained similar and were inversely proportional to FVC and SVC values. FVC and SVC at diagnosis can be used interchangeably as independent predictors of survival in both clinical and research settings.
Identifiants
pubmed: 32052165
doi: 10.1007/s00415-020-09751-1
pii: 10.1007/s00415-020-09751-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1615-1621Références
van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390:2084–2098. https://doi.org/10.1016/S0140-6736(17)31287-4
doi: 10.1016/S0140-6736(17)31287-4
pubmed: 28552366
Amyotrophic Lateral Sclerosis (ALS) Fact Sheet|National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet . Accessed 20 Mar 2019
Pinto S, de Carvalho M (2015) The R of ALSFRS-R: does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis? Amyotroph Lateral Scler Front Degener 16:120–123. https://doi.org/10.3109/21678421.2014.952641
doi: 10.3109/21678421.2014.952641
Lenglet T, Lacomblez L, Abitbol JL et al (2014) A phase II–III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol 21:529–536. https://doi.org/10.1111/ene.12344
doi: 10.1111/ene.12344
pubmed: 24447620
Czaplinski A, Yen AA, Appel SH (2006) Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 77:390–392. https://doi.org/10.1136/jnnp.2005.072660
doi: 10.1136/jnnp.2005.072660
pubmed: 16484652
pmcid: 2077717
Tilanus TBM, Groothuis JT, TenBroek-Pastoor JMC et al (2017) The predictive value of respiratory function tests for non-invasive ventilation in amyotrophic lateral sclerosis. Respir Res 18:144. https://doi.org/10.1186/s12931-017-0624-8
doi: 10.1186/s12931-017-0624-8
pubmed: 28743265
pmcid: 5526316
Pinto S, De Carvalho M (2015) Sessions 1–11. Amyotroph Lateral Scler Front Degener 16:1–62. https://doi.org/10.3109/21678421.2015.1089039
doi: 10.3109/21678421.2015.1089039
Magnus T, Beck M, Giess R et al (2002) Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 25:709–714. https://doi.org/10.1002/mus.10090
doi: 10.1002/mus.10090
pubmed: 11994965
Andrews JA, Meng L, Kulke SF et al (2018) Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol 75:58–64. https://doi.org/10.1001/jamaneurol.2017.3339
doi: 10.1001/jamaneurol.2017.3339
Singh D, Verma R, Garg RK et al (2011) Assessment of respiratory functions by spirometry and phrenic nerve studies in patients of amyotrophic lateral sclerosis. J Neurol Sci 306:76–81. https://doi.org/10.1016/j.jns.2011.03.039
doi: 10.1016/j.jns.2011.03.039
pubmed: 21496826
Lyall RA, Donaldson N, Polkey MI et al (2001) Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain J Neurol 124:2000–2013
doi: 10.1093/brain/124.10.2000
Jackson C, De Carvalho M, Genge A et al (2018) Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R. Amyotroph Lateral Scler Front Degener. https://doi.org/10.1080/21678421.2018.1497658
doi: 10.1080/21678421.2018.1497658
Enache I, Pistea C, Fleury M et al (2017) Ability of pulmonary function decline to predict death in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Front Degener 18:511–518. https://doi.org/10.1080/21678421.2017.1353097
doi: 10.1080/21678421.2017.1353097
Baumann F, Henderson RD, Morrison SC et al (2010) Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:194–202. https://doi.org/10.3109/17482960902991773
doi: 10.3109/17482960902991773
pubmed: 19452343
Pinto S, de Carvalho M (2017) Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Front Degener 18:86–91. https://doi.org/10.1080/21678421.2016.1249486
doi: 10.1080/21678421.2016.1249486
Traynor BJ, Zhang H, Shefner JM et al (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology 63:1933–1935
doi: 10.1212/01.WNL.0000144345.49510.4E
Kaufmann P, Levy G, Thompson JLP et al (2005) The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64:38–43. https://doi.org/10.1212/01.WNL.0000148648.38313.64
doi: 10.1212/01.WNL.0000148648.38313.64
pubmed: 15642901
Pinto S, de Carvalho M (2019) SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS. Front Neurol 10:109. https://doi.org/10.3389/fneur.2019.00109
doi: 10.3389/fneur.2019.00109
pubmed: 30873101
pmcid: 6403463
Pinto S, de Carvalho M (2017) Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotroph Lateral Scler Front Degener 18:528–533. https://doi.org/10.1080/21678421.2017.1354995
doi: 10.1080/21678421.2017.1354995
Chiò A, Mora G, Moglia C et al (2017) Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d’Aosta Register. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2017.1387
doi: 10.1001/jamaneurol.2017.1387
pubmed: 28692730
pmcid: 7112760
Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13–21
doi: 10.1016/S0022-510X(99)00210-5
Manera U, Calvo A, Daviddi M et al (2019) Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2019-321153
doi: 10.1136/jnnp-2019-321153
pubmed: 31871138
EFNS Task Force on Diagnosis, and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S et al (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. Eur J Neurol 19:360–375. https://doi.org/10.1111/j.1468-1331.2011.03501.x
doi: 10.1111/j.1468-1331.2011.03501.x
Polkey MI, Green M, Moxham J (1995) Measurement of respiratory muscle strength. Thorax 50:1131–1135
doi: 10.1136/thx.50.11.1131
Lechtzin N, Wiener CM, Shade DM et al (2002) Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest 121:436–442
doi: 10.1378/chest.121.2.436
Caruso P, de Albuquerque ALP, Santana PV et al (2015) Diagnostic methods to assess inspiratory and expiratory muscle strength. J Bras Pneumol 41:110–123. https://doi.org/10.1590/S1806-37132015000004474
doi: 10.1590/S1806-37132015000004474
pubmed: 25972965
pmcid: 4428848
Jackson CE, Rosenfeld J, Moore DH et al (2001) A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 191:75–78
doi: 10.1016/S0022-510X(01)00617-7
Fitting JW, Paillex R, Hirt L et al (1999) Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 46:887–893
doi: 10.1002/1531-8249(199912)46:6<887::AID-ANA11>3.0.CO;2-L
Pinto S, de Carvalho M (2018) Sniff nasal inspiratory pressure (SNIP) in amyotrophic lateral sclerosis: relevance of the methodology for respiratory function evaluation. Clin Neurol Neurosurg 171:42–45. https://doi.org/10.1016/j.clineuro.2018.05.011
doi: 10.1016/j.clineuro.2018.05.011
pubmed: 29807198
Capozzo R, Quaranta VN, Pellegrini F et al (2015) Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol 262:593–603. https://doi.org/10.1007/s00415-014-7613-3
doi: 10.1007/s00415-014-7613-3
pubmed: 25522696
Morgan RK, McNally S, Alexander M et al (2005) Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 171:269–274. https://doi.org/10.1164/rccm.200403-314OC
doi: 10.1164/rccm.200403-314OC
pubmed: 15516537
Matsuda C, Shimizu T, Nakayama Y, Haraguchi M (2019) Cough peak flow decline rate predicts survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 59:168–173. https://doi.org/10.1002/mus.26320
doi: 10.1002/mus.26320
pubmed: 30106482
Pinto S, Pinto A, de Carvalho M (2012) Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clin Neurophysiol 123:2454–2459. https://doi.org/10.1016/j.clinph.2012.05.012
doi: 10.1016/j.clinph.2012.05.012
pubmed: 22762911
Boentert M, Glatz C, Helmle C et al (2018) Prevalence of sleep apnoea and capnographic detection of nocturnal hypoventilation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 89:418–424. https://doi.org/10.1136/jnnp-2017-316515
doi: 10.1136/jnnp-2017-316515
pubmed: 29054915
pmcid: 29054915
Rafiq MK, Bradburn M, Proctor AR et al (2012) Using transcutaneous carbon dioxide monitor (TOSCA 500) to detect respiratory failure in patients with amyotrophic lateral sclerosis: a validation study. Amyotroph Lateral Scler 13:528–532. https://doi.org/10.3109/17482968.2012.688836
doi: 10.3109/17482968.2012.688836
pubmed: 22871078
Schiffman PL, Belsh JM (1993) Pulmonary function at diagnosis of amyotrophic lateral sclerosis: rate of deterioration. Chest 103:508–513
doi: 10.1378/chest.103.2.508
Chiò A, Canosa A, Gallo S et al (2011) ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology 77:1432–1437. https://doi.org/10.1212/WNL.0b013e318232ab9b
doi: 10.1212/WNL.0b013e318232ab9b
pubmed: 21956723
Van Eijk RPA, Westeneng H-J, Nikolakopoulos S et al (2019) Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. https://doi.org/10.1212/WNL.0000000000006855
doi: 10.1212/WNL.0000000000006855
pubmed: 32042914
pmcid: 6369899